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The epithelial-specific cell adhesion molecule (EpCAM) modulates cell adhesion and proliferation. Its over-
expression correlates with tumor cell proliferation, and EpCAM is a therapeutic target. In the February issue
of Nature Cell Biology, Maetzel et al. demonstrate that proliferative responses to EpCAM require regulated
intramembrane proteolysis and a nucleocytoplasmic intracellular domain fragment.
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PreviewsReceptor-activated proteins acting singly
(STATs) or in a cascade (Ras/MAP kinase)
are well-recognized surface-to-nucleus
signaling pathways. However, the
capacity of surface receptors to directly
translocate to the nucleus and affect
cellular functions is less accepted. While
a significant number of cell surface recep-
tors have been reported to translocate to
the nucleus, there are only a few examples
(Notch, APP, ErbB4, Ryk) in which the
translocation is ligand dependent and
has been convincingly shown to alter
nuclear function (Carpenter and Liao,
2008; Lyu et al., 2008; Ma et al., 2008).
There is, however, preliminary evidence
for several other candidates.
Establishment of nuclear function is
important, as the translocations, which
may involve a small fraction of the total
receptor pool, can otherwise be dis-
missed as trafficking side effects. In the
examples cited above, the mechanism
of surface-to-nucleus translocation in-
volves a two-step proteolytic processing
pathway. The initial step is ligand-acti-
vated cleavage of the ectodomain by an
ADAM metalloprotease. While the exact
biochemical mechanism that initiates
ectodomain cleavage is not clear, the cell
surface-associated fragment, containing
a few ectodomain residues, the trans-
membrane domain, and the intracellular
domain (ICD), is subsequently cleaved
within the transmembrane domain by
g-secretase to release the ICD fragment
into the cytoplasm. The soluble ICD frag-
ment, which may be metabolically
unstable, is then translocated to the
nucleus. In the process of nuclear translo-
cation, Notch, APP, and ErbB4 ICDs are
known to associate with transcription
factors and thereby influence gene
expression and cellular responses. To
date, none of these ICDs has been shownto directly recognize specific DNA
sequences.
Now, Maetzel and colleagues (2009)
have added another cell surface molecule
with significant implications in cancer
biology to this list. Epithelial-specific
cell adhesion molecule (EpCAM/CD326)
is a type I transmembrane glycoprotein
with an ectodomain, one transmembrane
domain, and a cytoplasmic domain of 26
residues (Baeuerle andGires, 2007; Trzpis
et al., 2007). It is specifically expressed in
epithelial tissue, is overexpressed in
some cancers, and is a homotypic adhe-
sion protein that can antagonize cad-
herin-mediated cell-cell adhesion (Litvi-
nov et al., 1994, 1997). In view of these
properties, EpCAM is a therapeutic target,
and there are several anti-EpCAM agents
in clinical trials (Baeuerle andGires, 2007).
Mechanistically, inducible expression
of EpCAM has been demonstrated to
provoke expression of c-myc and the
Myc target genes cyclin A and cyclin E
(Munz et al., 2004). Cells expressing
EpCAM proliferate more rapidly, grow in
an anchorage-independent manner, and
have a reduced requirement for growth
factors. Consistent with the growth-
promoting role of EpCAM, knockdown of
endogenous EpCAM in tumor cells
decreases cell proliferation and migration
(Munz et al., 2004; Osta et al., 2004).
However, relatively little is known about
the intracellular trafficking of EpCAM or
the means by which it communicates
with the nucleus.
Maetzel et al. have now taken a major
step toward elucidating the mechanism
by which EpCAM affects nuclear function.
The authors demonstrate that ADAM17
(TACE) and g-secretase sequentially
cleave EpCAM, producing a soluble ecto-
domain fragment and a 5 kDa ICD frag-
ment, respectively. The application ofCancer Cellrelatively selective inhibitors implicated
the above-mentioned proteases, as did
coprecipitation experiments that detected
ADAM17 and presenilin 2 (the protease
component of the g-secretase complex)
in association with EpCAM. The ICD frag-
ment was detected in the cytoplasm and
nucleus of experimental cells, but not
when protease inhibitors were present.
In the experiments presented, cells
were allowed to grow as islands, permit-
ting significant cell-cell contact and
presumably homotypic interactions that
provoke EpCAM cleavage. In support of
this, the authors show that addition of
soluble EpCAMectodomain to single cells
stimulates formation of the ICD fragment.
Examination of human normal and tumor
colonic tissue sections revealed EpCAM
ICD in the latter, but not in the former. On
the basis of these data, the cleavage of
EpCAM parallels that of a variety of other
cell surface adhesion molecules, such as
cadherin and CD44 (Carpenter and Liao,
2008). However, in many cases, including
cadherin and CD44, cleavage is provoked
by a nonspecific agent, such as TPA or
ionomycin. In contrast, ICD formation
from Notch, ErbB4, APP, and EpCAM
can be stimulated by biologically relevant
ligands. In the case of Ryk, ICD formation
is constitutive,while nuclear localization of
ICD requires Wnt, a Ryk ligand (Lyu et al.,
2008).
The question of the biological signifi-
cance of the EpCAM ICD fragment for-
mation was addressed via several
approaches. First, the ICD fragment was
exogenously expressed, and cellular
responses were measured. Second, the
capacity of TACE and/or g-secretase
pharmacologic inhibitors or siRNAs to
block EpCAM-dependent responses was
tested. To assess specificity issues in
these latter experiments, the ICD fragment15, March 3, 2009 ª2009 Elsevier Inc. 165
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Previewswas expressed in inhibitor-treated cells
to determine whether the ICD could
overcome inhibitor abrogation of cell
responses. Also, experiments were per-
formed in which endogenous EpCAM
expression was knocked down using
siRNA and the resulting decrease in cell
proliferation was reversed by exogenous
expression of the ICD fragment. These
lines of evidence all support the conclu-
sion that formation of the ICD is required
for EpCAM to stimulate cell proliferation.
The mechanism by which the ICD
modulates cell proliferation is proposed
to center on its association with ‘‘four
and a half LIM domain’’ protein 2 (FHL2),
a nucleocytoplasmic protein that interacts
with a large number of proteins, including
b-catenin, and that can function as
a cotranscriptional activator in several
systems (Johannessen et al., 2006). The
EpCAM ICD was detected in the nucleus
and cytoplasm as speckles, and the
authors report its presence in the nucleus
as a 650 kDa complex that also contains
FHL2, Lef1, and b-catenin. These same
proteins were also detected in electro-
phoretic mobility shift assays using
a Lef1 consensus sequence probe, and
formation of this complex was blocked
by TACE and g-secretase inhibitors. The
authors show that expression of the ICD
fragment in the absence of EpCAM can
induce c-myc expression and propose
that formation of the ICD complex with
the scaffolding protein FHL2 plus Lef1
and b-catenin accounts for the capacity166 Cancer Cell 15, March 3, 2009 ª2009 Eof EpCAM to stimulate c-myc expression
and cell proliferation. Lef1/TCF is known
to be a major regulator of c-myc expres-
sion.
The oncogenic potential of the ICD frag-
ment was demonstrated using a mouse
xenograft model, in which HEK293 cells
stably expressing EpCAM or the ICD frag-
ment produced nearly equivalent tumors.
As previously mentioned, gastrointestinal
tumor sections frequently exhibit nuclear
EpCAM ICD, while normal tissue sections
do not. The authors suggest that the
known upregulation of TACE and FHL2 in
tumors could serve as a reasonable expla-
nation for this observation.
These data provide substantial
evidence that the positive influence of
EpCAM on cell proliferation can be ac-
counted for by liberation of its ICD from
the plasma membrane. It remains to be
examined whether this mechanism may
be operative in other EpCAM-mediated
cellular responses, such as morphogen-
esis, differentiation, and inflammation
(Trzpis et al., 2007).
In terms of oncogenesis and ongoing
trials with EpCAM-targeted agents, it is
likely that absence of the ICD fragment
would constitute a biomarker for effective-
ness. Also, it is possible, as Maetzel et al.
suggest, that combinatorial therapy in
which anti-EpCAM together with TACE
and/org-secretase inhibitorsareemployed
could be a more effective therapeutic
approach than the use of anti-EpCAM
agents alone. However, this would likelylsevier Inc.entail a decrease in therapeutic specificity
given the broad spectrum of TACE and
g-secretase substrates.
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